Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCBT, SMHC referral · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| SMHC referral | ACTIVE_COMPARATOR | Referral to local Specialty Mental Health Care Services |
| BCBT | EXPERIMENTAL | Brief Cognitive Behavioral Therapy |
| Name | Type | Description |
|---|---|---|
| BCBT | BEHAVIORAL | Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks. |
| SMHC referral | BEHAVIORAL | Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.). |
Inclusion Criteria for depression: * Ages 11 to 17 years * Meet diagnostic criteria for Major Depression, Dysthymia, or Minor Depression * Live with a legal guardian Inclusion Criteria for anxiety: * Ages 7 to 17 years * Meet full or probable (missing one, non-core symptom) diagnostic criteria fo...
BCBT, also referred to as SMHC referral, is an investigational therapy being studied for depression. It is in Phase 2 clinical development. The therapy is being evaluated in a completed clinical trial that included patients with depression and anxiety.
BCBT is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ. The therapy is currently in Phase 2 clinical development for depression.
BCBT is in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. One Phase 2 clinical trial for the therapy has been completed.
BCBT has one completed clinical trial, identified as NCT00669526. This Phase 2 study, titled 'Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders,' enrolled 60 participants with depression and anxiety in the United States.
Yes, BCBT is also known as SMHC referral. Both names refer to the same investigational therapy being developed by Johnson & Johnson for depression.